Report on a biotech reallocating clinical resources by stopping several trials to prioritize leukemia and ALS treatment programs.
Key Takeaways
- AB Science discontinued three non-priority masitinib trials and suspended patient enrollment
- Halted studies targeted mast cell activation syndrome, mastocytosis, and progressive multiple sclerosis
- AB8939 completed Phase 1 Step 3 and will seek authorization for Phase 4 triple therapy